Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cognition Therapeutics, Inc

0.4549
+0.02826.61%
Post-market: 0.4410-0.0139-3.06%19:50 EDT
Volume:563.77K
Turnover:252.29K
Market Cap:28.19M
PE:-0.48
High:0.4654
Open:0.4200
Low:0.4200
Close:0.4267
Loading ...

Cognition Therapeutics Earnings Call: Progress Amid Challenges

TIPRANKS
·
22 Mar

Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ...

GuruFocus.com
·
21 Mar

Cognition Therapeutics Advances Alzheimer’s and DLB Trials

TIPRANKS
·
21 Mar

Cognition Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
20 Mar

Cognition Therapeutics FY 2024 EPS $(0.86) Misses $(0.76) Estimate

Benzinga
·
20 Mar

Cognition Therapeutics FY Net Income USD -33.971 Million

THOMSON REUTERS
·
20 Mar

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

THOMSON REUTERS
·
20 Mar

Press Release: Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Dow Jones
·
20 Mar

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

GlobeNewswire
·
14 Mar

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

GlobeNewswire
·
14 Mar

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

GlobeNewswire
·
10 Mar

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

GlobeNewswire
·
27 Feb

Cognition Therapeutics passes pre-defined futility analysis of Phase 2 study

TIPRANKS
·
26 Feb

Cognition VP co-hosting workshop at Neuroimmunology Drug Development Summit

TIPRANKS
·
25 Feb

Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

GlobeNewswire
·
25 Feb

Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

GlobeNewswire
·
20 Feb